+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

R

Actively Recruiting

This research aims to evaluate the clinical effectiveness, safety, and tolerability of XEN1101 when used alongside other antiseizure medications in adults with focal-onset seizures. It is a Phase 3, randomized, double-blind, placebo-controlled study involving approximately 360 participants. The study focuses on how XEN1101 affects seizure frequency compared to placebo while monitoring any side effects or safety concerns. Participants will be randomly assigned to one of three groups XEN1101 25 mg, XEN1101 15 mg, or placebo, taken once daily with an evening meal. The study includes a baseline period of up to 9.5 weeks to record seizure frequency, followed by 12 weeks of blinded treatment. After this, those who complete the treatment phase may join an open-label extension study for continued XEN1101 treatment, while others will enter an 8-week post-treatment follow-up period. During the study, participants will keep accurate seizure diaries and attend regular visits for assessments including seizure monitoring, safety checks, and tolerability evaluations. Researchers will measure the median percent change in focal seizure frequency from baseline through the 12-week treatment, along with other outcomes such as the proportion of participants experiencing significant seizure reduction and patient-reported global impressions. Safety is monitored from screening through 56 days after the final dose to ensure participant well-being throughout the trial.

Age: 18Years +All GendersPhase 3
103 locations
P

Actively Recruiting

Researchers are studying the effectiveness and safety of Afimkibart as an induction and maintenance treatment for people with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to evaluate how well Afimkibart works compared to a placebo in managing this condition. Participants will be randomly assigned to receive either Afimkibart or a placebo. Those receiving Afimkibart will get an intravenous IV infusion followed by subcutaneous SC injections. The study includes two experimental groups receiving Afimkibart and one group receiving placebo, both administered by IV and SC methods. The treatment and follow-up period extends through 52 weeks to assess both induction and maintenance therapy effects. During the study, participants will undergo evaluations including the Crohns Disease Activity Index CDAI for clinical remission and endoscopic assessments at week 52. Additional measurements at week 12 and throughout the study include symptom tracking, stool frequency, abdominal pain, quality of life questionnaires, and monitoring of adverse events. The total study duration may extend up to 70 weeks for safety follow-up and outcome assessments.

Age: 16Years - 80YearsAll GendersPhase 3
375 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of induction therapy using Afimkibart also called RO7790121 in adults with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to determine whether this treatment can induce clinical remission and improve endoscopic response compared to placebo. The trial is led by Hoffmann-La Roche and focuses on participants aged 16 to 80 years who have an inadequate response or intolerance to other Crohns disease treatments. Participants are randomly assigned to one of two groups one group receives Afimkibart initially through intravenous infusion followed by subcutaneous injections, while the other group receives a placebo intravenous infusion followed by Afimkibart subcutaneous injections. The study follows a parallel design with double-blinding to compare the effects of these treatment approaches over a 12-week induction period. During the trial, participants will undergo assessments including Crohns Disease Activity Index scoring, endoscopic evaluations, and symptom tracking such as stool consistency, abdominal pain, and fatigue. Researchers will monitor clinical remission, symptomatic relief, and adverse events up to 30 weeks after baseline. Quality of life will be measured with questionnaires, and biomarker subgroups will be analyzed. The studys total duration extends through 2033, with key measurements taken at week 12.

Age: 16Years - 80YearsAll GendersPhase 3
208 locations
E

Actively Recruiting

Researchers are evaluating the safety, pharmacokinetics, pharmacodynamics, and efficacy of RO7268489 as an add-on therapy to ocrelizumab in adults with progressive multiple sclerosis PMS. This phase II, multi-center, double-blind, placebo-controlled study aims to understand how RO7268489 affects disability progression and other clinical measures in PMS patients receiving ocrelizumab. The study is sponsored by Hoffmann-La Roche and involves randomized parallel groups. Participants will receive either one of three doses of RO7268489 or a matching placebo, each combined with ocrelizumab according to a predefined dosing schedule. After the double-blind treatment period, eligible participants may continue to receive open-label RO7268489 in an extension phase. The interventions involve drug administration per schedule alongside ongoing ocrelizumab treatment. During the study, participants will be monitored for up to approximately 110 weeks for disability progression and cognitive function using standardized tests and assessments. Researchers will measure brain volume changes, plasma levels of 2-arachidonoylglycerol and the study drug, and track adverse events including treatment discontinuations and suicidal ideation up to 5 years. This comprehensive monitoring includes clinical evaluations, imaging, and laboratory tests to assess safety and efficacy over the study and follow-up periods.

Age: 18Years - 60YearsAll GendersPhase 2
114 locations
E

Actively Recruiting

Researchers are evaluating XEN1101 as an additional treatment for people with primary generalized tonic-clonic seizures PGTCS in this Phase 3, multicenter, randomized, double-blind, placebo-controlled trial. The study aims to assess the clinical efficacy, safety, and tolerability of XEN1101 in subjects diagnosed with generalized epilepsy who are currently taking 1 to 3 anti-seizure medications ASMs. Participants must have probable or possible PGTCS and meet specific inclusion criteria. Participants aged 12 years and older will be randomly assigned to receive either XEN1101 or a placebo. Those 18 years and older will receive 25 mg of XEN1101 or placebo daily, while those between 12 and under 18 years may receive 15 mg, 25 mg, or placebo once daily with an evening meal. The study includes a baseline period lasting up to 9.5 weeks to monitor seizure frequency, followed by a 12-week double-blind treatment period. After completing this phase, participants can enter an open-label extension study to continue XEN1101 treatment or join an 8-week post-treatment follow-up. Throughout the study, participants will keep accurate seizure diaries and undergo assessments to measure the median percent change in monthly PGTCS frequency. The study will also monitor safety and tolerability during treatment. Those who do not continue into the extension phase will have follow-up visits for 8 weeks after treatment ends. Overall, the trial involves multiple visits and careful monitoring to evaluate the impact of XEN1101 as adjunctive therapy over several months.

Age: 12Years +All GendersPhase 3
141 locations
C

Actively Recruiting

Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.

All AgesAll Genders
305 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of LY4268989 compared to a placebo in adults with moderately to severely active ulcerative colitis UC. The study involves participants aged 18 to 80 who have had UC for at least three months and have active symptoms confirmed by specific scoring methods. This Phase 2 clinical trial is sponsored by Eli Lilly and Company and focuses on treatment effects over a long period. Participants will receive oral doses of LY4268989 or a matching placebo in a randomized, double-blind design. The study includes two experimental dose groups of LY4268989 and one placebo group. Treatment and evaluation will continue for up to approximately 108 weeks, excluding the screening period. During the trial, participants will be regularly assessed for clinical remission and response using the Modified Mayo Score at weeks 10 and 52. Researchers will monitor symptomatic responses and drug levels in the blood up to week 52. Safety and effectiveness data will be collected throughout the study, with the overall duration lasting up to about two years.

Age: 18Years - 80YearsAll GendersPhase 2
258 locations
R

Actively Recruiting

Researchers are evaluating treatments for participants with metastatic colorectal cancer who have a specific KRAS p.G12C mutation and have not received prior treatment. The study compares progression-free survival between two groups one receiving sotorasib, panitumumab, and FOLFIRI, and the other receiving FOLFIRI with or without bevacizumab-awwb. This is a phase 3 randomized trial aiming to understand which combination better manages the disease. Participants in one group take sotorasib daily as an oral tablet while receiving panitumumab and FOLFIRI every two weeks through intravenous infusions. The other group receives FOLFIRI every two weeks, with or without bevacizumab-awwb, also given by intravenous infusion every two weeks. The study treatments continue according to these schedules to compare their effects. Throughout the trial, participants will undergo assessments to measure progression-free survival using RECIST v1.1 criteria for up to approximately three years. Additional outcomes like overall survival, response rates, duration of response, and safety events are monitored for up to five years. Researchers will collect blood samples to measure sotorasib levels during early treatment cycles. Participants are closely observed through scheduled visits and tests to evaluate treatment effects and safety over the study duration.

Age: 18Years +All GendersPhase 3
291 locations
R

Actively Recruiting

This research aims to evaluate how reducing sedentary behavior and improving physical fitness can affect outcomes for adult women with obesity undergoing bariatric surgery. The study focuses on women aged 18 and older with a body mass index BMI between 30 and 45 kgm2 who are scheduled for either vertical sleeve gastrectomy or Roux-en-Y gastric bypass. It seeks to understand whether enhancing physical fitness before surgery can improve weight loss, reduce obesity-related complications, and improve quality of life after surgery, while also exploring molecular changes in muscle and fat tissues. Participants will engage in a structured sedentary behavior reduction program SBRPro delivered online via mobile apps, which encourages replacing sedentary time with physical activities tailored to individual abilities. The program begins about six months before surgery and continues through the first year after surgery. The study includes education sessions, aerobic and strength activities before surgery, and a progressive postoperative activity plan with remote support as needed. Weekly physical activity diaries will help monitor adherence, and participants will be grouped based on their engagement with the program. Throughout the study, participants will undergo assessments of physical fitness, body composition, muscle strength, and cardiorespiratory fitness at multiple time points before and after surgery. Blood samples and tissue biopsies collected during surgery will be analyzed to understand biological changes linked to physical activity. Researchers will measure outcomes such as total weight loss, obesity-related complications, and quality of life up to one year after surgery. The study duration spans from baseline assessment through 12 months post-surgery, with continuous monitoring of activity and health status.

Age: 18Years +FEMALEPhase Not Applicable
1 location

1-10 of 11

1